A. Fabi

A. Fabi, G. Cattozzo, C. Franzini, 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

R. Labianca, F. di Costanzo, P. Pedrazzoli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

D. Bruzzese, G. Arpino, A. Fabi, 2020, ESMO open.

Safety and Efficacy of Bevacizumab in Combination with First-Line Chemotherapy in Advanced Breast Cancer: Data from the Italian Cohort of the ATHENA Trial

D. Crivellari, A. Fabi, A. Bottini, 2014, Tumori.

The Experience of Oncology Healthcare Providers in the Central Italy during the COVID-19 Lockdown

G. Ciliberto, B. Vincenzi, F. Cognetti, 2020, Cancers.

Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial

F. Roila, G. Miccinesi, A. Fabi, 2022, Frontiers in Oncology.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

G. Arpino, K. Cannita, F. Montemurro, 2018, Breast.

Prepectoral vs. Submuscular Immediate Breast Reconstruction in Patients Undergoing Mastectomy after Neoadjuvant Chemotherapy: Our Early Experience

A. Di Leone, D. Terribile, S. Magno, 2022, Journal of personalized medicine.

Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life

P. Muti, M. Maschio, L. Dinapoli, 2012, Journal of Neuro-Oncology.

Is delayed chemotherapy-induced emesis well managed in oncological clinical practice?

G. Tonini, F. Cognetti, A. Fabi, 2003, Supportive Care in Cancer.

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

P. Marchetti, G. Tonini, I. Paris, 2021, Cancers.

HER2 change between primary and metastatic breast cancer 1 HER2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER: SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study

F. Cognetti, A. Fabi, P. Carlini, 2001, Cancer Chemotherapy and Pharmacology.

Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease

L. Marucci, A. Fabi, I. Sperduti, 2013, Journal of Neuro-Oncology.

How to restructure the management of Italian oncological patients during and after COVID-19 pandemic?

F. Cognetti, A. Fabi, G. Ferretti, 2020, European review for medical and pharmacological sciences.

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of baseline and on-treatment glycemia on everolimus-exemestane 1 efficacy in patients with hormone receptor-positive advanced breast 2 cancer: the EVERMET study

L. Mariani, G. Pruneri, G. Curigliano, 2021 .

Definition of a tool to assess shared decision‐making (SDM) on women with breast cancer: A value‐based approach

G. Tortora, A. Orlandi, A. Fabi, 2022, Health science reports.

BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making

G. Tortora, D. Generali, G. Scambia, 2022, Cancers.

Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features

M. Mottolese, F. Cognetti, A. Fabi, 2008 .

HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?

M. Mandalà, S. Di Cosimo, A. Alimonti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †

G. Tortora, P. Marchetti, I. Paris, 2020, Journal of personalized medicine.

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

V. Torri, L. Cavanna, D. Generali, 2022, Breast Cancer Research.

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

F. Puglisi, P. Vigneri, G. Arpino, 2022, Frontiers in Oncology.

The Effectiveness of the Sport "Dragon Boat Racing" in Reducing the Risk of Lymphedema Incidence: An Observational Study.

A. Fabi, D. Giannarelli, L. Iacorossi, 2018, Cancer nursing.

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer.

S. Barni, L. Cavanna, F. Puglisi, 2019, Clinical breast cancer.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid-associated thrombotic thrombocytopenic purpura.

F. Cognetti, A. Fabi, P. Carlini, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis

F. Cognetti, A. Fabi, A. Vidiri, 2018, In Vivo.

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

F. Cognetti, A. Fabi, A. Vidiri, 2018, Oncology.

Testis metastasis as an initial manifestation of an occult gastrointestinal cancer.

A. Vecchione, F. Marandino, F. Cognetti, 2004, Anticancer research.

Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?

G. Tortora, F. Puglisi, G. Arpino, 2022, Cancer treatment reviews.

Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer

G. Scambia, A. Di Leone, D. Terribile, 2022, Current oncology.

Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

F. Cognetti, A. Fabi, A. Vidiri, 2009, Anticancer research.

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme

M. Maschio, F. Cognetti, A. Fabi, 2009, Cancer Chemotherapy and Pharmacology.

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic

M. Mottolese, A. Fabi, O. Segatto, 2014, Journal of Molecular Medicine.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

D. Generali, F. Cognetti, A. Fabi, 2015, Future oncology.

Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis

M. Maschio, A. Fabi, D. Giannarelli, 2019, The International journal of neuroscience.

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

F. Cognetti, A. Fabi, P. Carlini, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting

A. Fabi, P. Malaguti, 2013, Expert opinion on pharmacotherapy.

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study

A. Fabi, E. Bria, G. Minniti, 2011, Supportive Care in Cancer.

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years

M. Filetti, G. Scambia, A. Fabi, 2022, Cancers.

The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma.

R. Floris, O. Schillaci, A. Fabi, 2015, Anticancer research.

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study

F. Cognetti, A. Fabi, D. Giannarelli, 2008, Supportive Care in Cancer.

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

I. Paris, A. Fabi, S. de Placido, 2020, BMC Cancer.

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.

A. Brandes, R. Agati, M. Reni, 2016, Neuro-oncology.

A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma

B. Casini, A. Fabi, A. Antenucci, 2018, Journal of Neuro-Oncology.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

G. Arpino, P. Marchetti, F. Cognetti, 2013, ClinicoEconomics and outcomes research : CEOR.

Clinicoeconomics and Outcomes Research

G. Arpino, P. Marchetti, F. Cognetti, 2022 .

Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?

S. Cosimo, F. Cognetti, A. Fabi, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Paget’s disease of the breast: Our 20 years’ experience

A. Di Leone, S. Magno, A. Sanchez, 2022, Frontiers in Oncology.

The lysosomal beta-D-N-acetylglucosaminidase isozymes in human plasma during pregnancy: separation and quantification by a simple automated procedure.

A. Fabi, A. Burlina, G. Tettamanti, 1989, Clinica chimica acta; international journal of clinical chemistry.

Behaviour of several enzymes of lysosomal origin in human plasma during pregnancy.

A. Fabi, A. Burlina, G. Tettamanti, 1984, Clinica chimica acta; international journal of clinical chemistry.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

L. Landi, G. Minuti, F. Cappuzzo, 2012, British Journal of Cancer.

Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group

M. Maschio, A. Fabi, D. Giannarelli, 2017, Epilepsy & Behavior.

Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life

P. Muti, M. Maschio, L. Dinapoli, 2011, Journal of Neuro-Oncology.

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis

I. Vitale, M. Mottolese, A. Fabi, 2015, Oncotarget.

Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

M. Mottolese, F. Cognetti, A. Fabi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER-2-positive metastatic breast cancer: trastuzumab and beyond

M. Mottolese, A. Fabi, G. Metro, 2008, Expert opinion on pharmacotherapy.

Adherence to Oral Administration of Endocrine Treatment in Patients With Breast Cancer: A Qualitative Study

A. Fabi, M. D. De Marinis, M. Piredda, 2016, Cancer nursing.

Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis.

A. Fabi, G. Metro, D. Pellegrini, 2007, Anticancer research.

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

M. Aapro, G. Steger, F. Roila, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine

D. Generali, A. Di Leone, I. Paris, 2023, Frontiers in Oncology.

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

G. Ciliberto, E. Pescarmona, F. Cognetti, 2021, Molecular cancer.

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.

A. Brandes, R. Agati, M. Reni, 2017, Oncotarget.

Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)

L. Prosperini, A. Fabi, G. Simonetti, 2021, Journal of Neurology.

Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital

G. Rasi, G. Tortora, G. Scambia, 2021, Journal of personalized medicine.

Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersocieties (SINch/AINO/SIN) document.

F. Angileri, A. Falini, A. Olivi, 2020, Journal of neurosurgical sciences.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

F. Cognetti, A. Fabi, M. Infante, 2019, Journal of Experimental & Clinical Cancer Research.

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients

M. Filetti, A. Fabi, G. Daniele, 2023, Current oncology.

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

E. Maiello, A. Fabi, V. Lorusso, 2017, Breast Cancer Research and Treatment.

Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study

A. Fabi, S. Masi, L. Conti, 2017, Breast Cancer Research.

A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?

M. Maschio, V. Zagonel, F. Cognetti, 2019, Future oncology.

Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.

A. Vecchione, A. Alimonti, F. Cognetti, 2005, Anticancer research.

Spine Surgery in Patients with Metastatic Breast Cancer: A Retrospective Analysis.

A. Fabi, I. Sperduti, A. Pompili, 2016, World neurosurgery.

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.

G. Curigliano, F. Puglisi, G. Arpino, 2023, Cancer treatment reviews.

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

V. Adamo, G. Curigliano, F. Puglisi, 2022, Cancers.

Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.

M. Maschio, F. Cognetti, A. Fabi, 2021, Future oncology.

Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

G. Arpino, F. Cognetti, A. Fabi, 2020, Future oncology.

Stability of enzymes of lysosomal origin in human cerebrospinal fluid.

L. Malesani, A. Fabi, A. Burlina, 1987, Clinica chimica acta; international journal of clinical chemistry.

Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

M. Mottolese, A. Sacchi, A. Fabi, 2008, PloS one.

Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study

A. Fabi, L. Giacomelli, A. Pace, 2021, BMC cancer.

Rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study

A. Fabi, L. Giacomelli, A. Pace, 2020 .

The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?

F. Cognetti, A. Fabi, D. Giannarelli, 2017, Breast.

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.

F. Puglisi, O. Garrone, F. Montemurro, 2022, The Lancet. Oncology.

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

M. Mottolese, S. Di Cosimo, F. Cognetti, 2008, Breast.

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

M. Milella, F. Cognetti, A. Fabi, 2007, The oncologist.

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification

E. Pescarmona, A. Sapino, M. Mottolese, 2017, Journal of Experimental & Clinical Cancer Research.

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

S. Barni, D. Generali, D. Santini, 2021, npj Breast Cancer.

Oligometastatic Breast Cancer: How to Manage It?

F. Cognetti, G. Scambia, I. Paris, 2021, Journal of personalized medicine.

Male breast cancer: 6-year experience.

A. Fabi, V. Di Carlo, M. Russillo, 2008, Minerva chirurgica.

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Emilio Bria, Antonello Vidiri, Stefano Telera, 2011, Journal of experimental & clinical cancer research : CR.

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

F. Cognetti, A. Fabi, P. Malaguti, 2016, Journal of experimental & clinical cancer research : CR.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

L. Crinò, M. Mottolese, F. Cognetti, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and

L. Crinò, M. Mottolese, F. Cognetti, 2010 .

Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer

M. Mandalà, F. Cognetti, A. Fabi, 2005, Breast Cancer Research and Treatment.

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

F. Cognetti, A. Fabi, G. Ferretti, 2007, Current opinion in obstetrics & gynecology.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study

M. Mottolese, M. Milella, A. Fabi, 2008, Breast Cancer Research.

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study

A. Ballestrero, P. Marchetti, D. Generali, 2022, Targeted Oncology.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

S. Margolin, M. Desilvio, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lobular Carcinoma of the Breast and Utility of Oncotype Dx®: a Retrospective Decision Impact Analysis.

S. Barni, A. Fabi, F. Petrelli, 2022, Clinical breast cancer.

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

S. Barni, D. Generali, D. Santini, 2021, npj Breast Cancer.

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy

M. Dieci, G. Tortora, F. Puglisi, 2023, Therapeutic advances in medical oncology.

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

F. Roila, A. Fabi, P. Bossi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Weight of epilepsy in brain tumor patients

M. Maschio, L. Dinapoli, A. Fabi, 2014, Journal of Neuro-Oncology.

Open Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical Series.

A. Fabi, I. Sperduti, L. Raus, 2019, World neurosurgery.

Kyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 cases

A. Fabi, I. Sperduti, A. Pompili, 2018, Clinical Neurology and Neurosurgery.

The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient’s dream study

F. Cognetti, A. Fabi, D. Giannarelli, 2022, Frontiers in Oncology.

Glioblastoma Patients: Role of Methylated MGMT

A. Fabi, G. Metro, 2011 .

Fluorescence microscopy study of polymorphonuclear leukocyte substrate attached materials.

H. Petty, A. Fabi, J. W. Francis, 1988, Cell motility and the cytoskeleton.

Behaviour of some lysosomal enzymes in the plasma of insulin dependent diabetic patients during artificial pancreas treatment.

A. Fabi, A. Burlina, G. Tettamanti, 1987, Clinical biochemistry.

Temozolomide Low-dose Chemotherapy in Newly Diagnosed Low-grade Gliomas: Activity, Safety, and Long-term Follow-up

M. Maschio, L. Marucci, A. Fabi, 2017, Tumori.

Phase II study of weekly carboplatin in pretreated adult malignant gliomas

M. Maschio, B. Casini, F. Cognetti, 2019, Journal of Neuro-Oncology.

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

F. Cognetti, L. Marucci, A. Fabi, 2014, BioMed research international.

Cognitive rehabilitation training in patients with brain tumor-related epilepsy and cognitive deficits: a pilot study

M. Maschio, L. Dinapoli, A. Fabi, 2015, Journal of Neuro-Oncology.

Neurocognitive evaluation in older adult patients affected by glioma.

A. Fabi, I. Terrenato, M. Carosi, 2020, Journal of geriatric oncology.

Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study

P. Muti, M. Maschio, L. Dinapoli, 2009, Neurological Sciences.

Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis

G. Scambia, C. Marchetti, I. Paris, 2021, Journal of personalized medicine.

Weekly schedule of vinorelbine in pretreated breast cancer patients

M. Milella, A. Fabi, R. D'Attino, 2000, Breast Cancer Research and Treatment.

A phase II trial of vinorelbine and thiotepa in metastatic breast cancer.

F. Cognetti, A. Fabi, S. Tomao, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

P. Bruzzi, R. Ponzone, O. Garrone, 2019, Journal of Clinical Oncology.

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

F. Montemurro, V. Rossi, F. Cognetti, 2019, Cancers.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

G. Arpino, D. Generali, K. Cannita, 2017, Oncotarget.

Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation

A. Fabi, C. Raggi, W. Malorni, 2015, Oncoimmunology.

Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines

G. Bepler, F. Cognetti, A. Fabi, 2011, Cancer Chemotherapy and Pharmacology.

Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.

A. Fabi, G. Ferretti, P. Papaldo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

G. Bepler, A. Monteiro, M. Schell, 2009, Cancer investigation.

Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.

M. Milella, F. Cognetti, A. Fabi, 2004, Journal of experimental & clinical cancer research : CR.

Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival.

G. Tortora, M. Brunelli, A. Fabi, 2016, Breast.

Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.

F. Cognetti, A. Fabi, S. Tomao, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study

F. Cognetti, A. Fabi, E. Magnani, 2000, Cancer Chemotherapy and Pharmacology.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

F. Cognetti, A. Fabi, D. Giannarelli, 2012, BMC Cancer.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

M. Marino, M. Mottolese, F. Cognetti, 2013, Expert opinion on pharmacotherapy.

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

F. Cognetti, A. Fabi, P. Malaguti, 2016, Journal of Experimental & Clinical Cancer Research.

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

V. Torri, D. Mavroudis, K. Zaman, 2018, Cancer Chemotherapy and Pharmacology.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

S. Cosimo, M. Pino, M. Mottolese, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings

M. Filetti, A. Fabi, G. Daniele, 2023, Cancers.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

M. Mottolese, M. Milella, F. Cognetti, 2008, Cancer Chemotherapy and Pharmacology.

Adherence to Oral Endocrine Therapy in Women with Breast Cancer: A Mixed Method Study

A. Fabi, M. Piredda, D. Giannarelli, 2016 .

The enzymatic breakdown of pantethine to pantothenic acid and cystamine.

A. Fabi, M. A. Rosei, S. Dupré, 1970, European journal of biochemistry.

Narrative medicine: feasibility of a digital narrative diary application in oncology

G. Sanguineti, F. Cognetti, A. Fabi, 2022, The Journal of international medical research.

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

S. Cosimo, M. Mandalà, S. Di Cosimo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience

A. Di Leone, D. Terribile, S. Magno, 2022, Cancers.

Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology

M. Fabrini, R. Soffietti, V. Zagonel, 2018, American journal of clinical oncology.

Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation

M. Maschio, A. Fabi, F. Piludu, 2012, Journal of experimental & clinical cancer research : CR.

Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.

F. Cognetti, A. Fabi, S. Fattoruso, 2013, Anticancer research.

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma

B. Casini, L. Prosperini, A. Fabi, 2015, Disease markers.

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidities in elderly patients with glioblastoma: a field-practice study.

B. Casini, L. Marucci, A. Fabi, 2019, Future oncology.

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

A. Santoro, M. Valerio, A. Fabi, 2021, Breast Cancer Research and Treatment.

Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.

A. Fabi, A. Vidiri, 2016, Translational lung cancer research.

Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.

M. Pino, S. Di Cosimo, F. Cognetti, 2004, Anticancer research.

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

M. Campiglio, S. Ménard, V. Adamo, 2013, Breast Cancer Research and Treatment.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease

S. Cosimo, M. Pino, M. Mottolese, 2006 .

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.

A. Ballestrero, P. Bruzzi, F. Puglisi, 2021, The Lancet. Oncology.

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

M. Mottolese, F. Cognetti, A. Fabi, 2006, Cancer Chemotherapy and Pharmacology.

Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study

A. Fabi, S. Masi, M. Carosi, 2017, Breast Cancer Research.

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

F. Puglisi, G. Arpino, D. Generali, 2021, ESMO open.

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.

V. Torri, A. Musolino, L. Ferrari, 2017, Breast.

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

L. Mariani, G. Pruneri, G. Curigliano, 2021, Clinical Cancer Research.

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

A. Musolino, A. Schirone, C. Ficorella, 2018, Oncotarget.

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

G. Ciliberto, E. Pescarmona, A. Martayan, 2018, Journal of experimental & clinical cancer research : CR.

Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).

V. Zagonel, M. Eoli, A. Fabi, 2015 .

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis

G. Tortora, A. Orlandi, A. Palazzo, 2023, EClinicalMedicine.

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

M. Aapro, F. Puglisi, M. Milella, 2011, Journal of experimental & clinical cancer research : CR.

Weekly epirubicin plus lonidamine in advanced breast carcinoma

M. Milella, A. Fabi, C. Garufi, 1999, Breast Cancer Research and Treatment.

Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting

A. Di Leone, D. Terribile, L. Scardina, 2023, Cancers.

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

F. Montemurro, E. de Azambuja, A. Fabi, 2023, EClinicalMedicine.

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.

Paolo Carlini, S. Di Cosimo, F. Cognetti, 2003, Drugs of today.

Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)

M. Desilvio, V. Semiglazov, X. Pivot, 2012 .

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

F. Cognetti, A. Fabi, M. Infante, 2019, Journal of experimental & clinical cancer research : CR.

Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial

M. Ceppi, F. Puglisi, O. Garrone, 2019, International journal of cancer.

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

S. Barni, L. Cavanna, L. Boni, 2015, PloS one.

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

S. Barni, L. Cavanna, L. Boni, 2015, PloS one.

Impact of epilepsy and its treatment on brain metastasis from solid tumors: A retrospective study

M. Maschio, A. Fabi, D. Giannarelli, 2022, Frontiers in Neurology.

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.

D. Bruzzese, F. Puglisi, G. Arpino, 2018, Breast.

The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy.

F. Cognetti, A. Fabi, L. Moscetti, 2019, Current Problems in Cancer.

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’

D. Bruzzese, G. Arpino, A. Fabi, 2021, ESMO Open.

Retroperitoneal liposarcoma with metastasis to both orbits: an unusual metastatic site.

F. Cognetti, A. Fabi, V. Ferraresi, 2005, Anticancer Research.

Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

G. Tortora, A. Orlandi, A. Palazzo, 2023, Therapeutic advances in medical oncology.

Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial

A. Fabi, E. Baldini, D. Grasso, 2022, Breast cancer.

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

F. Cognetti, A. Fabi, P. Malaguti, 2013, Anticancer research.

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

C. Fiore, F. Atzori, A. Orlandi, 2023, Frontiers in Oncology.

Erratum to: Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life

P. Muti, M. Maschio, L. Dinapoli, 2012, Journal of Neuro-Oncology.

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

M. Caterino, M. Mottolese, F. Cognetti, 2015, Drug design, development and therapy.

Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy

M. Maschio, M. Contin, L. Dinapoli, 2008, Journal of Neuro-Oncology.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.

A. Fabi, L. Marandino, M. Di Maio, 2023, European journal of cancer.

Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study

M. Maschio, L. Dinapoli, A. Fabi, 2012, Epileptic disorders : international epilepsy journal with videotape.

Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases

A. Fabi, M. Crecco, S. Marzi, 2009, Journal of experimental & clinical cancer research : CR.

Zonisamide in Brain Tumor–Related Epilepsy: An Observational Pilot Study

M. Maschio, L. Dinapoli, A. Fabi, 2017, Clinical neuropharmacology.

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification

E. Pescarmona, A. Sapino, M. Mottolese, 2017, Journal of experimental & clinical cancer research : CR.

Chemotherapy-induced amenorrhea in early breast cancer.

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

S. Di Cosimo, F. Cognetti, A. Fabi, 2006, Breast.

Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors

M. Dieci, G. Caprara, A. Fabi, 2021, Frontiers in Oncology.

Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC)

S. Cosimo, M. Mottolese, F. Cognetti, 2007 .

Chronobiological study of several enzymes of lysosomal origin in human plasma.

F. Halberg, A. Fabi, L. Caimi, 1989, Chronobiologia.

Leptomeningeal carcinomatosis in aggressive germ non-seminoma testicular tumor: A case report and review of literature

A. Fabi, T. Koudriavtseva, A. Savarese, 2012, Clinical neurology and neurosurgery (Dutch-Flemish ed. Print).

Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper.

L. Livi, F. Puglisi, G. Arpino, 2023, Clinical breast cancer.

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

M. Milella, F. Cognetti, A. Fabi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New target therapies for brain metastases from breast cancer.

A. Fabi, G. Metro, 2012, Current Cancer Drug Targets.

p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.

E. Pescarmona, M. Mottolese, F. Cognetti, 2020, Clinical breast cancer.

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report

G. Ciliberto, A. Fabi, P. Giacomini, 2023, Frontiers in Oncology.

Bone and lung metastases from intracranial meningioma.

F. Cognetti, A. Fabi, A. Vidiri, 2006, Anticancer research.

Paget’s disease of the breast: Our 20 years’ experience

A. Di Leone, S. Magno, A. Sanchez, 2022, Frontiers in Oncology.

Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women

M. Milella, F. Cognetti, A. Fabi, 1999, Breast Cancer Research and Treatment.

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

C. Criscitiello, G. Curigliano, G. Tortora, 2023, npj Breast Cancer.

Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab‐Based Therapy beyond Progression in HER‐2 Positive Metastatic Breast Cancer 1

M. Mottolese, F. Cognetti, A. Fabi, 2010, The breast journal.

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis

I. Vitale, M. Mottolese, A. Fabi, 2015, Oncotarget.

of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism:

S. Cosimo, F. Cognetti, A. Fabi, 2003 .

COX-2 targeting in cancer: a new beginning?

M. Milella, F. Cognetti, A. Fabi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum enzymes of lysosomal origin as indicators of the metabolic control in diabetes: Comparison with glycated hemoglobin and albumin

A. Fabi, L. Pinelli, A. Burlina, 1986, Acta diabetologia latina.

Behaviour of several enzymes of lysosomal origin in human plasma during whole blood storage.

A. Fabi, A. Burlina, G. Tettamanti, 1984, Clinica chimica acta; international journal of clinical chemistry.

An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy

A. Di Leone, L. Scardina, E. J. Mason, 2023, Journal of personalized medicine.